MapLight Therapeutics appoints Jonathan Gillis as interim CFO
MapLight Therapeutics has separated with CFO Vishwas Setia effective immediately. Jonathan Gillis has been appointed as the interim CFO, effective June 18, 2026, to oversee financial operations.
*this image is generated using AI for illustrative purposes only.
MapLight Therapeutics has appointed Jonathan Gillis as its interim Chief Financial Officer (CFO) following the separation of Vishwas Setia, effective immediately. Gillis will assume the role on June 18, 2026, ensuring continuity in the company's financial leadership during this transition period.
The company disclosed the executive changes in a recent regulatory filing. Vishwas Setia's departure from the position of CFO is effective immediately, marking a sudden shift in the company's financial oversight structure.
Jonathan Gillis steps into the interim role to manage the company's financial operations. The appointment is set to take effect on June 18, 2026, as MapLight Therapeutics looks to maintain stability in its financial reporting and strategic planning functions.
Executive Changes
The transition involves the following key personnel updates:
| Position | Executive | Status | Effective Date |
|---|---|---|---|
| CFO | Vishwas Setia | Separated | Immediately |
| Interim CFO | Jonathan Gillis | Appointed | June 18, 2026 |
MapLight Therapeutics has not provided further details regarding the reasons for the separation or the duration of Gillis's interim tenure. The company continues to focus on its operational objectives amidst this leadership change.
What criteria will MapLight use to select a permanent CFO, and how long is the search expected to take?
How might the leadership transition impact MapLight's ongoing clinical trials or strategic partnerships?
Will the interim CFO role influence any changes in the company's financial reporting or capital allocation strategies?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
